Dominic Norton discusses focusing on the shift to digital vulnerabilities, including securing IoT devices in the public ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Bristol-Myers Squibb offers 17.25% upside with strong growth prospects, cost-saving initiatives & an undervalued stock. Learn ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Substack by Magnus Ofstad. In this article, we will ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Indra and Rheinmetall signed a memorandum of understanding (MOU) on 13 March to upgrade the fire-control system and command, ...

Sofinnova Partners launches €165M Biovelocita II fund for early-stage science in Italy, France, UK & Denmark, backed by Amgen ...

The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...

The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...

Squibb Group’s liquidators say they have had “significant difficulty” finding millions of pounds worth of plant and other ...

As the demand for reliable and efficient energy storage grows, advanced battery management systems (BMS) are emerging as the ...

BMS said it will launch Cobenfy within the next few weeks and has set a price of $1,850 per month for the medicine, which is considerably more than the current, largely generic array of ...